
Lurbinectedin Plus Tecentriq Shows Promise for Hard-to-Treat Small-Cell Lung Cancer
People with advanced small-cell lung cancer (SCLC) who received lurbinectedin (Zepzelca) chemotherapy plus atezolizumab (Tecentriq) immunotherapy as a maintenance regimen after initial treatment had delayed disease progression and longer survival, …